New Evidence With BTK Inhibitor Therapy in MCL From ICML 2023
Gain insight into expert faculty perspectives as they discuss recent key studies from ICML 2023 on BTK inhibition in mantle cell lymphoma and their potential implications for clinical practice.
Decera Clinical Education Oncology Podcast · Catherine C. Coombs MD MS, Toby Eyre MBChB MD
Audio is streamed directly from the publisher (afp-928689-injected.calisto.simplecastaudio.com) as published in their RSS feed. Play Podcasts does not host this file. Rights-holders can request removal through the copyright & takedown page.
Show Notes
In this episode, Catherine C. Coombs, MD, and Toby Eyre, MBChB, MD, discuss key trials presented at ICML 2023 evaluating the use of BTK inhibitors in mantle cell lymphoma (MCL). The discussion includes analyses of:
- Phase II trial of acalabrutinib with rituximab for older patients with untreated MCL
- BRUIN: updated results of pirtobrutinib in covalent BTK inhibitor–pretreated MCL
- IMCL-2015 GELTAMO: 5-year update ibrutinib for untreated indolent MCL
Presenters:
Catherine C. Coombs, MD, MS
Associate Clinical Professor
Division of Hematology/Oncology, Department of Medicine
UCI Health
Orange, California
Toby Eyre, MBChB, MD
Honorary Senior Lecturer
Hematology and Cancer
University of Oxford
Consultant Hematologist
Department of Hematology
Hematology and Cancer Centre, Oxford University Hospitals NHS Foundation Trust
Oxford, United Kingdom
Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.